Relationship between PD-L1 expression and 18F-FDG uptake in gastric cancer
Authors:
Open Access
- 17 December 2019
- journal article
- research article
- Published by Impact Journals, LLC in Aging
- Vol. 11 (24) , 12270-12277
Abstract
Purpose: Immunotherapy has been successfully utilized for treatment of gastric cancer, so the identification of clinicopathologic features that are predictive of response to this therapy is crucial. F-18-FDG PET/CT can provide information on the molecular phenotype of many malignant tumors. The correlation between F-18-FDG accumulation and PD-L1/PD-L1-TILs status in gastric cancer patients has not been investigated. The aim of the current study is to assess whether F-18-FDG accumulation is associated with PD-Li/PD-Li-TiLs status, and whether F-18-FDG PET/CT may be useful for predicting PD-L1/PD-L1-TILs expression of gastric cancer. Results: Tumors with positive PD-L1 expression had higher SUVmax than in tumors with negative PD-L1 expression (15.0 +/- 8.0 vs. 7.2 +/- 4.2, respectively; P = 0.004). Tumors with positive PD-L1-TILs expression also had higher SUVmax than in tumors with negative PD-L1-TILs expression (10.3 +/- 6.5 vs. 6.6 +/- 3.7, respectively; P = 0.034). Multivariate analysis suggested that SUVmax remained significantly correlated with the status of PD-L1 (P = 0.043) and PD-L1-TILs (P = 0.016). PD-L1 expression was predicted with an accuracy of 67.2% when a SUVmax value of 8.55 was used as a cutoff point for analysis. Similarly, PD-L1-TILs expression was predicted with an accuracy of 64.2%, when a SUVmax value of 7.9 was used as the threshold for analysis. Conclusion: Higher F-18-FDG accumulation in gastric cancers is correlated with positive PD-L1/PD-L1-TILs expression. F-18-FDG PET/CT may be used to predict the status of PD-L1/PD-L1-TILs and thus aid in optimal treatment decision. Methods: A retrospective analysis was conducted on 64 patients with gastric cancer who underwent F-18-FDG PET/CT. SUVmax was calculated from the F-18-FDG accumulation of the primary tumor. The relationship between SUVmax and PD-L1/PD-L1-TILs status was analyzed.Keywords
This publication has 27 references indexed in Scilit:
- FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1The Oncologist, 2018
- Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancerNature Medicine, 2018
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialThe Lancet, 2018
- Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumabAnnals of Oncology, 2017
- Classifying Cancers Based on T-cell Infiltration and PD-L1Cancer Research, 2015
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- Management of advanced gastric cancerExpert Review of Gastroenterology & Hepatology, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010